184 related articles for article (PubMed ID: 35752582)
1. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gefapixant, a P2X
McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
[TBL] [Abstract][Full Text] [Related]
4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M
Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873
[TBL] [Abstract][Full Text] [Related]
6. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E; Patel M; Diab N; Wahab M; Zeraatkar D; Chu DK; O'Byrne PM; Guyatt GH; Satia I
JAMA; 2023 Oct; 330(14):1359-1369. PubMed ID: 37694849
[TBL] [Abstract][Full Text] [Related]
8. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR; Morice AH; Birring SS; Dicpinigaitis PV; Pavord ID; Assaid C; Kleijn HJ; Hussain A; La Rosa C; McGarvey L; Smith JA
ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33263037
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.
Chuang MH; Chen IW; Chen JY; Kang FC; Ho CN; Wu SC; Yew M; Lan KM; Hung KC
Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37197770
[TBL] [Abstract][Full Text] [Related]
11. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D; Green S
Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
[TBL] [Abstract][Full Text] [Related]
12. Gefapixant in two randomised dose-escalation studies in chronic cough.
Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
[TBL] [Abstract][Full Text] [Related]
14. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Dicpinigaitis PV; Birring SS; Blaiss M; McGarvey LP; Morice AH; Pavord ID; Satia I; Smith JA; La Rosa C; Li Q; Nguyen AM; Schelfhout J; Tzontcheva A; Muccino D
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):60-66. PubMed ID: 35569802
[TBL] [Abstract][Full Text] [Related]
15. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
Dicpinigaitis PV; Morice AH; Smith JA; Sher MR; Vaezi M; Guilleminault L; Niimi A; Gude K; Krahn U; Saarinen R; Pires PV; Wosnitza M; McGarvey L;
Lung; 2023 Jun; 201(3):255-266. PubMed ID: 37261531
[TBL] [Abstract][Full Text] [Related]
18. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
[TBL] [Abstract][Full Text] [Related]
19. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
[TBL] [Abstract][Full Text] [Related]
20. Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.
Nguyen AM; Schelfhout J; Muccino D; Bacci ED; La Rosa C; Vernon M; Birring SS
Ther Adv Respir Dis; 2022; 16():17534666221099737. PubMed ID: 35614875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
